



Press Release

ProStrakan Group plc

ProStrakan Launches Sancuso in US

Galashiels, Scotland, 3 November, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces the US launch of Sancuso[®], its novel, patent protected, transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving chemotherapy for up to five consecutive days.

This week's launch of Sancuso, the world's first licensed transdermal 5HT₃ receptor antagonist product, follows a week-long induction and training programme for ProStrakan's 67-strong US sales force, which has been established in collaboration with NovaQuest (the partnering group of Quintiles). Following the US Food and Drug Administration's approval of Sancuso in September, the sales force will now, for the first time, be permitted to promote Sancuso to oncologists and oncology nurses across the US, the world's largest pharmaceutical market.

Sancuso, which was developed in-house by ProStrakan, is a transdermal patch that delivers granisetron, an established 5HT₃ receptor antagonist, steadily into the bloodstream for up to seven days. Sancuso has been shown to be as efficacious as oral granisetron in preventing the side effects of nausea and vomiting in patients undergoing chemotherapy. Sancuso has the advantage of offering this protection through a single transdermal patch application, eradicating the need for injections or having to swallow multiple pills on a repeated daily basis, which is often not possible in cancer patients due to oral mucositis or tumour-related problems with swallowing.

Commenting on this week's US launch of Sancuso, Dr Wilson Totten, Chief Executive of ProStrakan, said:

"The launch of Sancuso in the US is a major achievement for ProStrakan and our new sales team is now fully equipped to introduce Sancuso to oncologists and oncology nurses across the US.

"With peak sales potential of more than \$100 million, Sancuso is being launched into a market worth \$1.3 billion and is the first of a number of products that we plan to launch in the US over the next two years."

Ends

For more information on this announcement, please contact:

ProStrakan Corporate +44 (0)1896 664000
Dr Wilson Totten, Chief Executive
Callum Spreng, Corporate Communications

Financial Dynamics +44 (0)20 7831 3113
David Yates / Ben Brewerton

Trout Group (for US investor enquiries)
Gitanjali Jain +1 (646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is situated in Galashiels in Scotland. The company's development capabilities are centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries.
www.prostrakan.com